NCT06893133 ctDNA-MRD Monitoring After Resection in Gastric Cancer
| NCT ID | NCT06893133 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University |
| Condition | Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 110 participants |
| Start Date | 2025-04-08 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 110 participants in total. It began in 2025-04-08 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and early intervention. Our previous retrospective study, using fixed ctDNA-MRD, confirmed that postoperative ctDNA-MRD can predict recurrence risk. Therefore, we plan to conduct a further prospective, multicenter, observational study, utilizing a combination of personalized ctDNA-MRD and fixed MRD panels, to dynamically monitor gastric cancer patients who have received neoadjuvant therapy followed by curative resection. The study will systematically analyze the correlation between ctDNA-MRD status and tumor recurrence and metastasis, assess its sensitivity and specificity in recurrence prediction, and compare its early warning advantage over traditional imaging techniques in predicting recurrence.
Eligibility Criteria
Inclusion Criteria: 1. Patients have received neoadjuvant therapy and radical resection (R0). 2. Pathologically confirmed ypTNM stage II-III gastric or gastroesophageal junction adenocarcinoma. 3. Patients must be able to provide sufficient fresh tissue/biopsies or minimum 5-10 FFPE sections for NGS-WES analysis. 4. Patients must be able to follow the study visit schedule and be willing to cooperate with the study by providing blood samples at the indicated time point. Exclusion Criteria: 1. Patients who could not receive enhanced CT, gastroscopy and other routine review after surgery. 2. Patients who could not perform WES or ctDNA-MRD detection for various reasons after surgery. 3. Other cases considered unsuitable for inclusion by researchers.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06893133 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06893133 currently recruiting?
Yes, NCT06893133 is actively recruiting participants. Contact the research team at ziyu_li@hsc.pku.edu.cn for enrollment information.
Where is the NCT06893133 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06893133 clinical trial?
NCT06893133 is sponsored by Peking University. The trial plans to enroll 110 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.